MiDiálisis mobile app with Bluetooth scale and smartband for people on peritoneal dialysis
Official title: Pilot Study of MiDialisis App Usage (Estudio Piloto de Uso de MiDiálisis App)
Run by Hospital Universitario 12 de Octubre · NCT07326085 · Data updated 2026-11-12
This pilot will try a smartphone app plus a Bluetooth scale and smartband to help adults on peritoneal dialysis track weight, vitals, and activity and share the data with their care team.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 55 (estimated) |
| Sponsor | Hospital Universitario 12 de Octubre Academic / other |
| Locations | 1 site (Madrid, Madrid) |
| Status | Recruiting |
| Started | July 27, 2025 |
| Main results expected | January 24, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT07326085 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) on chronic peritoneal dialysis for at least three months, clinically stable, who have a compatible smartphone or tablet, internet access, and can provide informed consent.
✕Probably not a fit
Patients without smartphone access or skills, those with pacemakers or implantable cardioverter-defibrillators (which preclude multifrequency body-composition measurement), those scheduled for imminent transplant, or with life expectancy under six months may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will pilot the MiDiálisis platform, a free smartphone app developed by the Technical University of Madrid, at Hospital 12 de Octubre. Adult patients on peritoneal dialysis who have been on PD for at least three months and who own a smartphone or tablet will install the app and connect a Bluetooth digital scale and a smartband. Patients will manually enter blood pressure and ultrafiltration values while the scale sends weight and body-composition data and the smartband transmits heart rate, sleep, and activity metrics to the app. The study will measure feasibility, adherence, and patient acceptance of the platform.
Why it matters
Potential benefit: If successful, the platform could simplify home monitoring and help patients and clinicians detect problems earlier and communicate more easily.
How similar studies have gone: Other small studies of remote monitoring in dialysis populations have shown feasibility and improved patient engagement, but integrated smartphone platforms like MiDiálisis remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years of age. * Patients with chronic kidney disease who have been on PD for at least 3 months in the same hospital. * Patients with a stable clinical condition during the 3 months prior to entering the study, defined as no unscheduled hospitalizations or major cardiovascular events (myocardial infarction or stroke) during that period. * Availability of a smartphone or tablet and internet access for the patient/caregiver. * Patients who understand the nature of the study and sign the informed consent form. Exclusion Criteria: * Patients with limitations for multifrequency body composition measurement (pacemaker or implantable cardioverter defibrillator wearers, and pregnant women). * Patients who do not routinely use a smartphone or are unfamiliar with the use of mobile applications. * Patients who are scheduled for a living kidney transplant in the next 6 months. * Patients with a life expectancy of less than 6 months. * Patients in a peritoneal ultrafiltration program due to cardiorenal syndrome.
Where it's running
-
Hospital 12 de Octubre
Madrid, Madrid, Spain Recruiting
Study contacts
- Principal investigator: Claudia Yuste Lozano, PhD — Hospital 12 de Octubre
- Study coordinator: Aida Frias, MD
- Email: midialisispuma@gmail.com
- Phone: +34667805030
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Guiding Optimal Blood Pressure in Peritoneal Dialysis
This pilot tests whether aiming for a lower systolic blood pressure target (<120 mmHg) is feasible and practical for adults with end-stage kidney disease on peritoneal dialysis, compared to a <140 mmHg target.
-
Synbiotic capsules for adults on peritoneal dialysis
This study tests whether daily synbiotic capsules can reduce inflammation and improve nutrition in adults with CKD on peritoneal dialysis compared with a placebo.
-
Plant-focused diet to improve nutrition in malnourished adults on peritoneal dialysis.
This trial will test whether a plant-focused diet helps malnourished adults on peritoneal dialysis improve their nutrition and health over six months.
-
Sensor-based congestion alert for people on peritoneal dialysis
This study tests whether the Bodyport Cardiac Scale can help predict worsening fluid overload events in adults receiving automated peritoneal dialysis.
-
Starting peritoneal dialysis gradually with an incremental prescription
This trial will test whether beginning adults on peritoneal dialysis with a lower, gradually increased dose (incremental PD) works as well as starting full-dose PD for people who are just starting dialysis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.